Barinthus’ HPV-related cancer therapy proves safety, but not efficacy
Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high-risk human papillomavirus (hrHPV)-associated cervical cancer is safe. | Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high risk human papillomavirus-associated cervical cancer is safe. But the failure to prove the therapy actually works has left the biotech mulling how to take the candidate further.